Whalesbook
Torrent Pharmaceuticals Ltd. has officially assumed controlling promoter status at JB Chemicals & Pharmaceuticals Ltd. following the completion of its acquisition of a 46.39% stake. The transaction, valued at ₹11,917 crore, closed on January 21, 2026, after Torrent purchased the shares from KKR's entity, Tau Investment Holdings Pte. Ltd. This move signifies a significant strategic play to bolster Torrent's presence in the branded generics market.
Leadership Shake-up
The change in control necessitated an immediate restructuring of JB Pharma's governance. Three non-executive directors — Gaurav Trehan, Akshay Tanna, and Prashant Kumar — resigned from the board. Simultaneously, Whole-time Director and Chief Executive Officer Nikhil Chopra tendered his resignation, stepping down from his director role immediately. Chopra will continue as CEO only until March 31, 2026, before exiting the company entirely.
New Management Takes Charge
Aman Mehta, widely recognized for his role as Managing Director at Torrent Pharma and instrumental in past acquisitions like Unichem and Curatio, has been appointed the new Managing Director of JB Pharma. His three-year term is expected to usher in a period of deep operational integration and strategic oversight. Three additional directors, Amal Kelshikar, Hasmukh Patel, and Sudhir Menon, have also joined the board, bringing extensive industry experience and financial acumen.
Strategic Rationale
The acquisition positions Torrent Pharmaceuticals to leverage JB Pharma's established franchises in key therapeutic areas, including gastrointestinal, hypertension, and pediatrics. Torrent aims to accelerate portfolio expansion and supply-chain integration, driving margin improvements and consolidating its India-focused growth strategy. The deal values JB Pharma at approximately ₹25,689 crore on a fully diluted basis, with further components including an open offer and employee share acquisition.